Molecular Targets and Cancer Therapeutics (Part 1)

Author(s): Rawiah A. Alsiary*, Hanadi A. Katouah, Hiba S. Al-Amodi and Mashael Al-Toub

DOI: 10.2174/9789815080384123010007

Biology of Cancer

Pp: 86-186 (101)

Buy Chapters
  • * (Excluding Mailing and Handling)

Molecular Targets and Cancer Therapeutics (Part 1)

Biology of Cancer

Author(s): Rawiah A. Alsiary*, Hanadi A. Katouah, Hiba S. Al-Amodi and Mashael Al-Toub

Pp: 86-186 (101)

DOI: 10.2174/9789815080384123010007

* (Excluding Mailing and Handling)

Abstract

Loss of genomic stability in the cell due to defects in the checkpoint of DNA damage, mitotic checkpoint, and telomere maintenance led to increased incidences of base pair alterations. Therefore, that genomic instability plays a critical role in tumor initiation and progression. Tumor progression requires a dynamic tumor/normal exchange in their microenvironment to support tumor growth. The histological alteration seen in the tumor at early stages confirms that the surface between the epithelium and the stroma undergoes progressive disturbance. Tumor progression is also affected by the immune system in which chronic inflammations promote the growth of tumor. Tumor cells experience altered metabolic profiling to support their growth. Cancer cells are characterized by uncontrolled cell division. For that, they utilize glucose as a source of energy to help them grow faster than normal cells. Hence, Glycolysis is a key metabolomics pathway consumed at a high rate during carcinogenesis.